argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients

Parexel appoints Gwyn Bebb to lead oncology clinical development

Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need

Boehringer Ingelheim begins clinical development for fibrotic diseases

‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention

Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors

The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health

Merck doubles down on cardio-pulmonary breakthroughs

At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure